Biorestorative Therapies, Inc. (BRTX)
NASDAQ:BRTX
BRTX Stock Chart & Stats
$1.18
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.18
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$0.19 - $2.05
Previous CloseN/A
Volume34.37K
Average Volume (3M)8.17M
Market Cap
$6.55M
Enterprise Value$700.97K
Total Cash (Recent Filing)$2.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding25,478,170
10 Day Avg. Volume2,443,532
30 Day Avg. Volume8,165,362
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit3.04
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$8.00Price Target Upside577.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$1.90M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalBlinded Phase 2 data show many patients experienced meaningful reductions in pain and improvements in function, suggesting a potential therapeutic signal for BRTX-100.
Commercialization PartnershipA strategic collaboration to expand marketing and commercialization of consumer-facing biocosmeceutical products creates a new pathway to generate non‑clinical revenue.
Trial Enrollment And Development TimelineFull enrollment of the Phase 2 study establishes a clear timeline to a topline readout and supports the possibility of advancing the program into a Phase 3 trial.
Bears Say
Data Uncertainty Due To BlindingThe blinded status of trial data creates uncertainty about how much of the observed improvement is attributable to the treatment versus a placebo effect.
Ongoing Funding Needs And Execution RiskThe company is likely to need additional capital before Phase 2 results are available, raising execution risk and the possibility of further dilution.
Share Dilution From FinancingA recent public offering provided limited capital and caused substantial share dilution, which can depress shareholder value and signal financing challenges.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $0.19 and its highest was $2.04 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $6.55M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is May 20, 2026 which is in 34 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.04.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Undervalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 25,478,170 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went down -4.516%.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
BRTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(577.97% Upside)
Technical Analysis
Cellectar Biosciences
―
Marker Therapeutics
―
Cocrystal Pharma
―
Sensei Biotherapeutics
―
AEON Biopharma
―
Ownership Overview
1.72% Insiders
0.47% Mutual Funds
0.53% Other Institutional Investors
97.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---